Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications

被引:50
作者
Garcia, Andres [1 ]
Mack, Peter [1 ]
Williams, Stuart [1 ]
Fromen, Catherine [2 ]
Shen, Tammy [3 ]
Tully, Janet [1 ]
Pillai, Jonathan [4 ]
Kuehl, Philip [5 ]
Napier, Mary
DeSimone, Joseph M. [2 ,3 ,4 ]
Maynor, BenjaminW. [1 ]
机构
[1] Liquidia Technol, Res Triangle Pk, NC 27709 USA
[2] North Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA
[3] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
[4] Univ North Carolina Chapel Hill, Dept Chem, Chapel Hill, NC 27599 USA
[5] Lovelace Resp Res Inst, Albuquerque, NM 87108 USA
关键词
D O I
10.1155/2012/941243
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Particle Replication in Non-Wetting Templates (PRINT (R)) is a platform particle drug delivery technology that coopts the precision and nanoscale spatial resolution inherently afforded by lithographic techniques derived from the microelectronics industry to produce precisely engineered particles. We describe the utility of PRINT technology as a strategy for formulation and delivery of small molecule and biologic therapeutics, highlighting previous studies where particle size, shape, and chemistry have been used to enhance systemic particle distribution properties. In addition, we introduce the application of PRINT technology towards respiratory drug delivery, a particular interest due to the pharmaceutical need for increased control over dry powder characteristics to improve drug delivery and therapeutic indices. To this end, we have produced dry powder particles with micro-and nanoscale geometric features and composed of small molecule and protein therapeutics. Aerosols generated from these particles show attractive properties for efficient pulmonary delivery and differential respiratory deposition characteristics based on particle geometry. This work highlights the advantages of adopting proven microfabrication techniques in achieving unprecedented control over particle geometric design for drug delivery.
引用
收藏
页数:10
相关论文
共 36 条
[1]  
[Anonymous], 2008, EUR PHARM 5 0 DAT IN
[2]  
[Anonymous], 2011, STUD EV SAF TOL SEAS
[3]   Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation [J].
Bakker, E. M. ;
Volpi, S. ;
Salonini, E. ;
van der Wiel-Kooij, E. C. ;
Sintnicolaas, C. J. J. C. M. ;
Hop, W. C. J. ;
Assael, B. M. ;
Merkus, P. J. F. M. ;
Tiddens, H. A. W. M. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (06) :1328-1335
[4]   Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers [J].
Cass, LMR ;
Brown, J ;
Pickford, M ;
Fayinka, S ;
Newman, SP ;
Johansson, CJ ;
Bye, A .
CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :21-31
[5]   Role of target geometry in phagocytosis [J].
Champion, JA ;
Mitragotri, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (13) :4930-4934
[6]   What is the role of particle morphology in pharmaceutical powder aerosols? [J].
Chan, Hak-Kim .
EXPERT OPINION ON DRUG DELIVERY, 2008, 5 (08) :909-914
[7]   Particle engineering for pulmonary drug delivery [J].
Chow, Albert H. L. ;
Tong, Henry H. Y. ;
Chattopadhyay, Pratibhash ;
Shekunov, Boris Y. .
PHARMACEUTICAL RESEARCH, 2007, 24 (03) :411-437
[8]   Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development [J].
Crowder, TM ;
Rosati, JA ;
Schroeter, JD ;
Hickey, AJ ;
Martonen, TB .
PHARMACEUTICAL RESEARCH, 2002, 19 (03) :239-245
[9]   Dry powder platform for pulmonary drug delivery [J].
Daniher, Derek Ivan ;
Zhu, Jesse .
PARTICUOLOGY, 2008, 6 (04) :225-238
[10]   Large porous particles for pulmonary drug delivery [J].
Edwards, DA ;
Hanes, J ;
Caponetti, G ;
Hrkach, J ;
BenJebria, A ;
Eskew, ML ;
Mintzes, J ;
Deaver, D ;
Lotan, N ;
Langer, R .
SCIENCE, 1997, 276 (5320) :1868-1871